# NCI Awards Numiera $2.3M SBIR Grant

The National Cancer Institute (NCI) awarded Numiera Therapeutics a **$2.3 million Direct-To-Phase II SBIR grant** on September 21, 2026, to advance clinical trials of etomoxir, a novel CPT1 inhibitor targeting glioblastoma. This funding supports a dose-escalation study to evaluate safety, pharmacology, and initial efficacy, potentially enabling progression to later-phase clinical trials for this aggressive brain cancer.

- This grant represents a significant federal investment in innovative oncology therapeutics, highlighting opportunities for biotech firms specializing in cancer drug development.
- Procurement professionals should note the emphasis on translational research funding mechanisms like Direct-To-Phase II SBIR grants that accelerate clinical development timelines.
- Contractors and industry stakeholders can leverage this precedent to pursue similar NIH/NCI funding for early-stage clinical trials in oncology and related fields.
- The involvement of a Colorado-based company underscores regional biotech innovation hubs as focal points for federal research funding.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** September 21, 2026

### Government Entities
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)

### Vendors
- Numiera Therapeutics (awardee)

### Sources
- [
  Numiera Therapeutics Awarded NCI Direct-To-Phase II SBIR Grant to Advance Etomoxir Into Clinical Trials for Glioblastoma
  
](https://www.einpresswire.com/article/944016246/numiera-therapeutics-awarded-nci-direct-to-phase-ii-sbir-grant-to-advance-etomoxir-into-clinical-trials-for-glioblastoma) - EIN Presswire